Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
NCT06084338
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This trial tests if the combination of comprehensive metastasis directed therapy delivered by a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed by testosterone replacement, is an effective treatment for metastatic castration resistant prostate cancer. All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted radiopharmaceutical therapy with cessation of castration.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- December 31, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA · West Los Angeles, CA
Illinois · 1
- Edward Hines Jr. VA Hospital, Hines, IL · Hines, IL
Indiana · 1
- Richard L. Roudebush VA Medical Center, Indianapolis, IN · Indianapolis, IN
Michigan · 1
- VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.